AI
CLYM

Allostery Investments’s Climb Bio CLYM Stock Holding History

Allostery Investments’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-244,988
Closed -$299K – 46
2025
Q1 		$299K Hold
244,988
– – 0.43% 31
2024
Q4 		$441K Buy
+244,988
New +$886K 0.46% 33

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Allostery Investments's CLYM Position: Q2 2025 in Review

Allostery Investments sold out of Climb Bio (CLYM) in Q2 2025, closing a stake of 244,988 shares — an estimated $299K sold.

Allostery Investments first reported a position in CLYM in Q4 2024 and held it in 2 quarters. The position peaked at $441K in Q4 2024. 69 funds tracked by Wall St. Rank hold CLYM as of Q2 2025.

  • Allostery Investments reported no remaining Climb Bio position as of Q2 2025 after selling out during the quarter.
  • Allostery Investments sold 244,988 Climb Bio shares in Q2 2025, an estimated $299K.
  • Allostery Investments first reported a position in Climb Bio in Q4 2024 and held it in 2 quarters.
  • Allostery Investments's Climb Bio position peaked at $441K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Climb Bio as of Q2 2025.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.